Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 31.4% | 46.1% | 56.5% | 53.4% | 59.0% | 40.8% | 49.6% | 52.8% | 32.5% | 13.8% | 5.8% | 16.1% | 20.2% | 13.4% | 13.0% | 10.8% | 25.9% | (1.0%) | 6.6% | 18.1% |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Microsoft Corp's last 12-month Return on Equity (ROE) is 18.5%, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Return on Equity (ROE) for AstraZeneca PLC have been 12.5% over the past three years, and 14.7% over the past five years.
As of today, AstraZeneca PLC's Return on Equity (ROE) is 18.5%, which is lower than industry median of 18.5%. It indicates that AstraZeneca PLC's Return on Equity (ROE) is Bad.